Starpharma Holdings Ltd (ASX:SPL) Quarterly Activities Report to Dec 31, 2008
Starpharma Holdings Ltd (ASX:SPL)(PINK:SPHRY) Quarterly Activities Report to Dec 31, 2008
Companies in the News
Biotech
Australian Market Report of January 30: Ending Three-Day Rally
On Thursday, the Australian shares rose for the third consecutive day led by rallies in overseas markets and strong commodities prices. The benchmark S&P/ASX200 index was up 30.7 points, or 0.88 per cent, at 3,526.2, while the broader All Ordinaries index had gained 26.2 points, or 0.76 per cent, to 3,461.3. The Australian market might lose its recent gains following the heavy fall in Wall St.
Biota Holdings Limited (ASX:BTA) UK GOVERNMENT ORDERS 10.6 MILLION COURSES OF RELENZA
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that GlaxoSmithKline (GSK) has been awarded a significant contract by the UK Department of Health for 10.6 million treatment courses of RelenzaTM (zanamivir).
Australian Market Report of January 20: Bad News from UK
Australian shares yesterday closed higher after the lift of commodities prices. The benchmark S&P/ASX200 index was up 38.4 points, or 1.08 per cent, at 3,589.3, while the broader All Ordinaries index advanced 36.1 points, or 1.03 per cent, to 3,531 after a positive lead from Wall Street on Friday.
Mesoblast Limited (ASX:MSB) Stem Cells Approved For World First Osteoathritis Clinical Trial
Regenerative Stem Cell/medicine company Mesoblast Limited (ASX:MSB)(PINK:MBLTY) announced that it had received Australian institutional ethics approval to begin the first trial of adult stem cell treatment for prevention of knee osteoathritis.
Mesoblast Limited (ASX:MSB) Named 2009 North American Emerging Company By Frost & Sullivan
Regenerative medicine company Mesoblast Limited (ASX:MSB)(PINK:MBLTY) announced today that it has received the 2009 Frost & Sullivan Emerging Company Award in the United States Soft Tissue Repair market.
Starpharma Holdings Ltd (ASX:SPL) Dendrimer Reduces Toxicity of Cancer Drug
Starpharma Holdings Ltd (ASX:SPL)(PINK:SPHRY) today reported an important advance in its dendrimer-based drug-delivery program.
◂Previous Page
Biotech Next Page▸
Banking & Finance
- VIDEO: Lion Selection Group Ltd (ASX:LSX) CEO Hedley Widdup and Sean Russo Talk at the Australian Gold Conference 2024
- VIDEO: The Australian Gold Conference 2024 - Education Evening with Expert Panel
- Lithium Universe Ltd (ASX:LU7) Finalises Frankfurt and US OTC Listing
- ISX Financial Reports Strong Q2 2024 Results, Highlighting Robust Growth and Innovation
- NSX Limited (ASX:NSX) Company Update
- ASIC vs iSignthis Ltd and Nickolas John Karantzis
Oil Gas & Energy
- TMK Energy Limited (ASX:TMK) LF-07 Intersects 54 Metres of net Coal
- Central Petroleum Limited (ASX:CTP) Live Online Investor Presentation
- State Gas Limited (ASX:GAS) Quarterly Activities Report
- Beetaloo Energy Australia Limited (ASX:BTL) Quarterly Activities Report - 30 June
- Basin Energy Ltd (ASX:BSN) Quarterly Activities Report
- Central Petroleum Limited (ASX:CTP) Share Buy-Back
Life Sciences
- Ellis Martin Report: Redefining Cancer Treatment - RenovoRx, Inc. (NASDAQ:RNXT) CEO Shaun Bagai on Targeted Pancreatic Therapy
- BPH Energy Limited (ASX:BPH) Quarterly Activities Report
- Proteomics International Laboratories Ltd (ASX:PIQ) Quarterly Activities/Appendix 4C Cash Flow Report
- Proteomics International Laboratories Ltd (ASX:PIQ) Next-Gen PromarkerD Test Performance Results Published
- Proteomics International Laboratories Ltd (ASX:PIQ) OxiDx Test Detects Muscle Damage in Thoroughbred Racehorses
- Proteomics International Laboratories Ltd (ASX:PIQ) AMA Grants Reimbursement Code for Next-Gen PromarkerD Test
Social Media
